Drug duo takes on smoking cravings
NCT ID NCT04198116
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether combining two medications, varenicline and guanfacine, helps people quit smoking better than standard treatments. 167 adult smokers who smoked at least 10 cigarettes daily took part. Researchers measured how long participants could delay their first cigarette and how stress affected their smoking.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
167 people
The number who actually took part.
- Started
-
Nov 2020
- Finished
-
Apr 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 18+ 2. Able to read and write English 3. SMOKER: 10 or more cigarettes per day for at least the past year, Carbon Monoxide (CO) \> 10 ppm at intake 4. Able to take oral medications and willing to adhere to medication regimen 5. Provide evidence of a stable living residence in the last 2 months prior to randomization, have reasonable transportation arrangements to the study site, have no plans to move within the next 3 months, and have no unresolved legal problems 6. Motivated to quit smoking (8 or greater on the Contemplation Ladder) Exclusion Criteria: 1. Subjects with any significant current medical conditions (neurological, cardiovascular \[including hypertension or hypotension: sitting BP \>160/100 or \<90/60mmHg at baseline screening\], endocrine, thyroid, renal, liver), seizures, delirium or hallucinations, or other unstable medical conditions 2. Current Diagnostic and Statistical Manual of Mental Disorders (DSM-V) alcohol or substances use disorders, other than mild alcohol use disorder or tobacco use disorder 3. Subjects who have a positive test result at intake appointment on urine drug screens conducted for illicit drugs 4. Past 30 day use of psychoactive drugs excluding anxiolytics and antidepressants (however, see #10; barbiturates, benzodiazepines are exclusionary) 5. Women who are pregnant or nursing, or fail to use one of the following methods of birth control unless she or partner is surgically sterile or she is postmenopausal (hormone contraceptives \[oral, implant, injection, patch, or ring\], contraceptive sponge, double barrier \[diaphragm or condom plus spermicide\], or IUD) 6. Suicidal, homicidal or evidence of current (past 6-month) severe mental illness such as schizophrenia or bipolar disorder 7. meeting DSM-V criteria for current (past-6 month) attention deficit hyperactivity disorder (ADHD) 8. Individuals who are currently taking medications known to be effective for smoking cessation (e.g., FDA smoking cessation medications, nortriptyline, clonidine) or are regular users of e-cigarettes or other tobacco projects (pipe, cigar, smokeless tobacco) in the past 30 days 9. Only one member per household can participate in the study 10. Specific exclusions for administration of guanfacine not already specified: EKG evidence at baseline screening of any clinically significant conduction abnormalities or arrhythmias; known intolerance for guanfacine or any alpha blocker; history of fainting, syncopal attacks, heart failure or myocardial infarction, or impaired liver (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\] \> 3x normal) or renal function (estimated creatinine clearance \<60 cc/min); treatment with any antihypertensive drug or any alpha-blocker; use of any central nervous system (CNS) depressant (e.g., phenothiazines, barbiturates, benzodiazepines) 11. Specific exclusions for the administration of varenicline not already specified: known intolerance to varenicline or taking H2blockers (e.g., Cimetidine), quinolones, or trimethoprim.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Smoking cessation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yale University
New Haven, Connecticut, 06519, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Texts and wearables team up to help latinos quit smoking and get moving
- Can an AI chatbot help cancer patients kick the habit?
- Does the clock matter? scientists randomize when Quit-Smoking chatbots ping you
- Can a WhatsApp message help smokers quit?
- Practice quitting: a new way to help smokers who Aren't ready to stop?
- Can a Quit-Smoking program built for transgender adults help them stop?